Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
785
NCT02683928
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2016
Completion: Jun 30, 2017
NCT02829372
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
Phase: Phase 1
Start: May 31, 2016
Completion: May 31, 2019
NCT03309111
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
Start: Oct 25, 2017
Completion: Dec 15, 2023
NCT03568162
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Start: May 31, 2018
Completion: Aug 3, 2021
NCT03983395
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
Phase: Phase 1/2
Start: Apr 8, 2020
Completion: Jul 24, 2020
NCT05427812
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Start: Sep 27, 2022
Completion: Nov 19, 2024
NCT05862012
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Start: Nov 1, 2023
Completion: Jul 31, 2027
NCT07167914
A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants
Start: Sep 30, 2025
Completion: Apr 30, 2026